Lilly’s solbinsiran shows promise in mid-stage study

Eli Lilly (NYSE: LLY) is advancing its ambitions in cardiometabolic medicine with new mid-stage data showing that solbinsiran, an RNA interference therapy targeting ANGPTL3, can meaningfully reduce key lipid markers in patients with mixed dyslipidemia.

Findings from the Phase II PROLONG-ANG3 study, published Monday in The Lancet and presented at the American College of Cardiology meeting, show a 14% placebo-adjusted reduction in apolipoprotein B (apoB), the study’s primary endpoint.

Broader effects were also observed with this dose. Non-HDL cholesterol fell by 26%, LDL cholesterol by 17%, and triglycerides and very low-density lipoprotein cholesterol by just over 50%.